| |
References
|
Phase
|
Sample size
|
Mean age
|
HLA
|
Lymph node
|
DTH (mm2)-case
|
DTH (mm2)-control
|
CD8+ T-cell (%)-case
|
Recurrence (%)
|
Overall survival (%)
|
DFS (%)
|
|---|
|
Case
|
Control
|
Case
|
Control
|
Case
|
Control
|
Pre
|
Post
|
Pre
|
Post
|
Pre
|
Post
|
Case
|
Control
|
Case
|
Control
|
Case
|
Control
|
|---|
|
GP2
|
aMittendorf [12]/Tommy [10]
|
II
|
89
|
91
|
49
|
A2+
|
A2+
|
51N+
|
60N+
|
4.1
|
15.3
|
3.9
|
8
|
0.8
|
1.5
|
5.12
|
2.35
|
92.13
|
95.6
|
82.9
|
80.4
|
|
Clifton [30]
|
I
|
17
|
0
|
47
|
A2+, A3+
| |
13N+
| |
28
|
68
| | |
46*106
|
144*106
| | | | | | |
|
Carmichael [11]
|
I
|
18
|
0
|
47
|
A2+
| |
18N−
| |
0
|
27.5
| | |
0.4
|
1.1
| | | | | | |
|
GP2 Total
|
3 trials
| |
124
|
91
| | | | | | | | | | | | | | | | | |
|
E75
|
Clifton [7]
|
II
|
136
|
139
|
51
|
A2+, A3+, A24+, A26+
| |
81N+
|
88N+
|
1.6
|
7.9
|
2
|
2.1
|
0.025
|
0.09
|
8.82
|
14.4
| | |
89.8
|
83.8
|
|
Clifton [32]
|
II
|
81
|
69
|
52
|
A2+, A3+, A24+, A26+
|
A2+, A3+, A24+, A26+
|
49N+
|
44N+
| | | | | | | | | | | | |
|
Mittendorf [8]
|
III
|
382
|
376
|
51.8
|
A2+, A3+
|
A2+, A3+
|
373N+
|
366N+
| | | | | | |
6.3
|
9.8
| | |
77.1
|
77.5
|
|
Mittendorf [9]
|
I, II
|
108
|
79
|
55
|
A2+, A3+
|
A2−, A3−
|
53N+
|
44N+
|
1.2
|
13.7
|
0.4
|
1.7
| | |
10
|
20
| | |
89.7
|
80.2
|
|
Mittendorf [33]
|
I, II
|
106
|
76
|
55
|
A2+, A3+
|
A2−, A3−
|
51N+
|
43N+
| | | | | | |
5.6
|
13.1
| | |
94.3
|
86.8
|
|
Holmes [34]
|
I, II
|
53
|
0
|
58
|
A2+, A3+
| |
27N+
| |
NA
|
99.4
| | |
0.3
|
0.99
| | | | | | |
|
Patil [22]
|
I, II
|
106
|
81
|
56
|
A2+, A3+
|
A2−, A3−
|
46N+
|
53N+
|
3
|
14
|
3.2
|
3.5
| | |
8.3
|
14.8
| | | | |
|
Gates [35]
|
I
|
24
|
22
|
63
|
A2+
|
A2−
| | |
5
|
31.5
|
1.6
|
9.7
| | |
28.6
|
26.3
|
95.2
|
100
| | |
|
Benavides [36]
|
II
|
85
|
66
|
54
|
A2+, A3+
|
A2−,
|
49N+
|
42N+
|
4
|
14.84
|
NA
|
1.1
|
0.73
|
1.83
|
11.7
|
18.2
|
98.8
|
92.42
| | |
|
Peoples [20]
|
II
|
101
|
85
|
57
|
A2+, A3+
|
A2−, A3−
|
45N+
|
46N+
|
0.5
|
14
|
1.4
|
2.1
|
0.39
|
1.8
|
5.6
|
14.2
|
99
|
95.1
|
92.5
|
77
|
|
Holmes [23]
|
II
|
99
|
0
| |
A2+, A3+
| |
48N+
| |
2.7
|
21.5
| | |
0.416
|
1.78
|
10.1
| | | | | |
|
Amin [27]
|
II
|
101
|
85
| |
A2+, A3+
|
A2−, A3−
|
45N+
|
46N+
|
12.8
|
13.625
|
NA
|
2.64
|
0.42
|
1.79
|
8.3
|
14.8
|
99
|
93.8
|
88
|
58
|
|
Stojadinovic [37]
|
I
|
16
|
NA
|
52
|
A2+
| |
16N+
| |
NA
|
22.3
|
NA
|
3
|
0.36
|
0.65
| | | | | | |
|
Dehqanzada [38]
|
I, II
|
36
|
0
|
59.7
|
A2+
|
A2−
|
12N+
| | | | | | | | | | | | | |
|
Dehqanzada [39]
|
I, II
|
32
|
0
|
57
|
A2+
| |
10N+
| | | | | | | | | | | | | |
|
Hueman [40]
|
II
|
7
|
17
| |
A2+
|
A2−
|
7N−
|
17N−
| | | | |
58.8
|
67.4
| | | | | | |
|
Hueman [41]
|
I
|
22
|
22
| |
A2+
|
A2−
|
22N−
|
22N−
| | | | |
0.75
|
1.2
| | | | | | |
|
Mittendorf [42]
|
I
|
44
|
0
| |
A2+
|
A2−
|
24N+
| | | | | |
0.5
|
1.68
| | | | | | |
|
Peoples [21]
|
I
|
24
|
29
| |
A2+
|
A2−
|
24N+
|
29N+
|
NA
|
33
|
NA
|
7
|
0.56
|
1.66
|
8.3
|
20.7
|
100
|
93
|
85.7
|
59.8
|
|
Murray [43]
|
I
|
13
|
0
|
48
|
A2+
| |
6N+
| |
NA
|
7.83
| | | | | | | | | | |
|
Knutson [44]
|
I
|
4
|
10
|
48
|
A2+
|
A2+
| | | | | | | | | | | | | | |
|
E75 Total
|
21 trials
| |
1580
|
1156
| | | | | | | | | | | | | | | | | |
- NA not available, DTH delayed hypersensitivity reaction, HLA human leukocyte antigen, DTH delayed-type hypersensitivity reaction, DFS disease-free survival rate, HLA-A2± A2± human leukocyte antigen A2 positive/negative, HLA-A3± A3± human leukocyte antigen A3 positive/negative , HLA-A24± A24± human leukocyte antigen A24 positive/negative, HLA-A26± A26± human leukocyte antigen A26 positive/negative
- aTommy A(2020) and Mittendorf EA(2016) 17reported the same clinical trial
